Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
· zealand pharma
AI Briefing
- survodutide achieves significant weight loss in Phase 3 trial
- reduces body weight by 16.6% in people with obesity or overweight
- shows meaningful metabolic improvement in Phase 3 trial of dual glucagon/GLP-1 agonist
Advertisement